CPDR Patient Education Program
Industry-Sponsored Clinical Trials and Projects
The CRC maintains a comprehensive portfolio of both investigator-initiated and industry sponsored clinical trials that cover the entire patient's "life cycle." Some of the trials, though industry sponsored, are investigator-initiated trials for which a proposal was submitted by CPDR to obtain funding. All trials and projects are carried out with full approval of the respective IRBs.
CPDR Open Clinical Trials
ProstAtak TrialA randomized trial of ProstAtak in combination with standard external beam radiation therapy with or without androgen deprivation therapy is in men with intermediate to high risk localized prostate cancer. ProstAtak is an investigational product that is meant to kill tumor cells and elicit an anti-tumor vaccine effect. In a Phase II clinical trial of ProstAtak given with radiation, prostate cancer recurrence was three-fold lower than typically seen with radiation alone. The purpose of this Phase III trial is to definitively determine if ProstAtak reduces prostate cancer recurrence
BAYER 15396 ERA 223A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride (radium 223 dichloride is FDA approved drug that targets prostate cancer in the bones), in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer
RMOR3-SVA phase 3, randomized, open-label, multi-center, controlled study of Galeterone compared to Enzalutamide in men expressing androgen receptor splice variant-7 mRNA (AR-V7) with metastatic (M1) castrate resistant prostate cancer (CRPC). Galeterone is a selective, multi-targeted, small molecule drug for the treatment of castrate resistant prostate cancer
CONTACT Information: Judith A. Travis, RN, Walter Reed National Military Medical Center, Center for Prostate Disease Research, America Building 19, Room 3225 on the 3rd floor.
301-319-2927 or Judith.firstname.lastname@example.org
Quarterly Guest Speakers
Dr. Philip Arlen
National Cancer Institute
Topic: "Prostate Cancer: An Overview and Update of Novel Treatment Modalities"
There have been remarkable advances in the therapy for prostate cancer over the past decade. We will be discussing these advances as well as new treatment options in clinical trials.
Date: Thursday 5 May 2016
Location: Walter Reed National Military Medical Center (America Building, 2nd floor, Room 2525) and Fort Belvoir Community Hospital (via video teleconference in Oaks Pavilion, 1st floor, Room 332).
Read the MAY 2016 WRNMMC UsToo! Newsletter
February 2, 2016
CPDR Urology Residents Take Top Awards at 2016 James C. Kimbrough Urological Seminar
Urology Residents conducting research at The Center for Prostate Disease Research (CPDR), Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center presented their research at the Residents Competition category of the James C. Kimbrough Urological Seminar, San Diego, 2016.
January 11, 2016
A Novel Gene Alteration Associates with Aggressive Prostate Cancer in African American Men
The USU, Walter Reed-Bethesda and JPC collaborative team, through comprehensive evaluations of matched cohorts of African American and Caucasian American prostate cancers, previously established a higher frequency of ERG alterations in Caucasians (50-70%) and its significantly lower frequency in African Americans (20-25%). These intriguing observations actually provided the rational for the current study focusing on whole genome evaluations of prostate cancers from these two patient populations.